¹⁶¹Tb-PSMA-617 showed superior in-vitro and in-vivo results as compared to ¹⁷⁷Lu-PSMA-617, confirming theoretical dose calculations that indicate an additive therapeutic effect of conversion and Auger electrons in the case of ¹⁶¹Tb. These data warrant more preclinical research for in-depth investigations of the proposed concept, and present a basis for future clinical translation of ¹⁶¹Tb-PSMA-617 for the treatment of mCRPC.
No takes yet. Share an insight, caveat, or question.
Müller et al. (2019) studied this question.